Trial with human leucocyte interferon and vidarabine in herpes simplex virus encephalitis: diagnostic and therapeutic problems.
A combination therapy of human interferon, vidarabine, and dexamethasone was administered to six patients with proven (Patients I-III) or presumed (Patients IV-VI) herpes simplex virus encephalitis (HSVE). Interferon combined with dexamethasone was given to one patient with presumed HSVE (Patient VII). Leucopenia and elevated serum transaminase levels appeared in all patients and a diffuse bleeding in one of them. Patients II, III and IV died, 26, 43, and 209 days after the onset of encephalitis, respectively. Patients I, V, VI, and VII were left with moderate brain damage although their physical condition was good. HSV encephalitis presents diagnostic difficulties, complementary diagnostic methods are needed, and current therapeutic trials must be considered as preliminary.
D000328:Adult; D001921:Brain / Q000473:pathology; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004569:Electroencephalography; D004671:Encephalitis, Arbovirus / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006561:Herpes Simplex / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D008828:Microbiological Techniques; D008875:Middle Aged; D014057:Tomography, X-Ray Computed; D014740:Vidarabine / Q000627:therapeutic use*
D003907:Dexamethasone; D007372:Interferons; D014740:Vidarabine